News

For Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, myopia management is best started sooner rather than later.

A real-world pilot across 8 optometric sites found Qlosli (0.4% pilocarpine) implementation met or exceeded all corporate KPIs, with UWF imaging utilization rising 16.4 percentage points and 72.7% of patients achieving personal treatment goals.

GATHER2 OLE data through 3.5 years show avacincaptad pegol reduced GA lesion growth by 28.8% in continuously treated patients and 37% to 40% in those switched from sham, with no new safety signals.

Anna Tichenor, OD, PhD, FAAO, details her poster – one of AOA 2026's Top Five posters – that identified how quickly and how meaningfully patients experience symptom improvement, and which types of symptoms are affected.

A VA case report documents rapid PDR progression to intravitreal anti-VEGF treatment in a patient 6 months after semaglutide initiation, reinforcing AOA monitoring guidance for GLP-1 patients with preexisting DR.

Mohammad Rafieetary, OD, FAAO, FORS, DipABO, ABCMO, details his portion of the "Myopia Matters: Managing Risk, Vision Loss and Control" presentation.

Mark Wells, OD, weighs in on the new parameter range expected for the Acuvue Oasys 1-Day for Astigmatism lens.

Expanded astigmatism parameters are expected for PRECISION1, PRECISION7, and TOTAL30 contact lenses.

New preservative-free cyclosporine 0.05% single-use drops target dry eye inflammation, dosing, and safety.

New phase 3 trial tests rhNGF eye drops for persistent corneal epithelial defects, aiming for full healing and a first approved PCED therapy.

The company said the expanded portfolio will be available in the US and Canada this summer.

The investment will expand ACUVUE contact lens manufacturing and distribution in Jacksonville, improving supply chain stability for optometrists by 2028.

A newly developed diagnostic system, CaptureTumor (CaT), driven by AI and designed specifically for smartphone deployment, achieved diagnostic accuracy comparable to that of a specialist-graded slit-lamp evaluation for detecting rare ocular surface malignancies.

In this podcast, experts Francis Mah, MD; and Amy Nau, OD, FAAO, Dipl, CCLRT; discuss how to identify neurotrophic keratitis in practice, highlighting indications for corneal sensitivity testing based on patient history and examination findings. Faculty will also examine how to stage and treat neurotrophic keratitis once diagnosed.

The update introduces a 250 kHz scan speed for OCT Angiography combined with enhanced TruTrack Active Eye Tracking, as well as new multimodal imaging capabilities, including the Green Autofluorescence Module.

Epion completes phase 3 follow-up for EpiSmart epi-on corneal cross-linking in keratoconus, advancing toward FDA NDA and a less painful alternative.

A case study that highlights the importance of multimodal imaging in practice for early identification of rare inherited retinal dystrophies.

Oculis launches a genotype-guided dry eye trial testing licaminlimab eye drops, targeting TNFR1 patients and measuring Day 29 ocular discomfort improvement.

The lens is scheduled to become available in the US in fall 2026.

The study, conducted through the OHDSI network, analyzed records from 227,971 new users of semaglutide.

Daniel C. Brocks, MD, BostonSight chief medical officer, discusses a few of the company's studies, the patients they serve, and what the broader eye care community may be missing.

The free web-based tool guides eye care providers through evidence-based amblyopia diagnosis and treatment without requiring pediatric subspecialty training.

LENZ Therapeutics licenses FDA-approved presbyopia drop to Everest Medicines for Greater China; NDA under review by NMPA with approval anticipated in Q1 2027.

Researchers analyzed data from 13 randomized controlled trials involving children and adolescents with myopia.

Clark Chang, OD, MSA, MSc, FAAO, FSLS, and Susan Gromacki, OD, MS, FAAO, FSLS, provide insights into their expertise.

The strength of our referral relationships defines the quality of our patients' eye health journey.

Mile Brujic, OD, FAAO, details his experience in manufacturing his new ScleralEase device and what other ODs can learn from his experience.

Researchers from Yale School of Medicine weigh in on what everyday clinicians can take away from their findings.